LOX and neoplasm: Similar to the survival benefits induced by LOX inhibition (Figure 1, K and L), we found that CLOCK inhibition using SR9009 combined with anti-PD1 therapy resulted in survival extension, but did not cure any tumor-bearing mice, in CT2A and 005 GSC models (Supplemental Figure 6, A and B).